83 related articles for article (PubMed ID: 11355848)
1. In vitro assembly of novel cholera toxin-like complexes.
Hatic SO; McCann JA; Picking WD
Anal Biochem; 2001 May; 292(2):171-7. PubMed ID: 11355848
[TBL] [Abstract][Full Text] [Related]
2. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
[TBL] [Abstract][Full Text] [Related]
3. Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems.
Harakuni T; Sugawa H; Komesu A; Tadano M; Arakawa T
Infect Immun; 2005 Sep; 73(9):5654-65. PubMed ID: 16113283
[TBL] [Abstract][Full Text] [Related]
4. [A fusion protein of rotavirus VP6 and cholera toxin B subunit: expression in Escherichia coli and analysis of biological activities].
Guo TX; Fang RX; Li GH; Qian Y
Sheng Wu Gong Cheng Xue Bao; 2001 Nov; 17(6):621-5. PubMed ID: 11910752
[TBL] [Abstract][Full Text] [Related]
5. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity.
Agren LC; Ekman L; Löwenadler B; Nedrud JG; Lycke NY
J Immunol; 1999 Feb; 162(4):2432-40. PubMed ID: 9973526
[TBL] [Abstract][Full Text] [Related]
6. ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity.
Lycke N
Ann N Y Acad Sci; 2004 Dec; 1029():193-208. PubMed ID: 15681758
[TBL] [Abstract][Full Text] [Related]
7. Fusion proteins containing the A2 domain of cholera toxin assemble with B polypeptides of cholera toxin to form immunoreactive and functional holotoxin-like chimeras.
Jobling MG; Holmes RK
Infect Immun; 1992 Nov; 60(11):4915-24. PubMed ID: 1399002
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and assembly of an adjuvanted Porphyromonas gingivalis fimbrial antigen fusion protein in plants.
Shin EA; Lee JY; Kim TG; Park YK; Langridge WH
Protein Expr Purif; 2006 May; 47(1):99-109. PubMed ID: 16275129
[TBL] [Abstract][Full Text] [Related]
9. Lincomycin-induced over-expression of mature recombinant cholera toxin B subunit and the holotoxin in Escherichia coli.
Arimitsu H; Tsukamoto K; Ochi S; Sasaki K; Kato M; Taniguchi K; Oguma K; Tsuji T
Protein Expr Purif; 2009 Oct; 67(2):96-103. PubMed ID: 19410003
[TBL] [Abstract][Full Text] [Related]
10. A plant-based multicomponent vaccine protects mice from enteric diseases.
Yu J; Langridge WH
Nat Biotechnol; 2001 Jun; 19(6):548-52. PubMed ID: 11385459
[TBL] [Abstract][Full Text] [Related]
11. Oral immunization induces local and distant mucosal immunity in swine.
Hyland K; Foss DL; Johnson CR; Murtaugh MP
Vet Immunol Immunopathol; 2004 Dec; 102(3):329-38. PubMed ID: 15507316
[TBL] [Abstract][Full Text] [Related]
12. [Construction of mucosal vaccine derived from HBV surface antigen epitope A and the assay of its immunogenicity].
Liu X; Yang G; Qiu B; Tian P
Wei Sheng Wu Xue Bao; 2001 Oct; 41(5):625-9. PubMed ID: 12552813
[TBL] [Abstract][Full Text] [Related]
13. Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection.
Singh SR; Hulett K; Pillai SR; Dennis VA; Oh MK; Scissum-Gunn K
Vaccine; 2006 Feb; 24(8):1213-24. PubMed ID: 16194585
[TBL] [Abstract][Full Text] [Related]
14. Characterization of fluorescent chimeras of cholera toxin and Escherichia coli heat-labile enterotoxins produced by use of the twin arginine translocation system.
Tinker JK; Erbe JL; Holmes RK
Infect Immun; 2005 Jun; 73(6):3627-35. PubMed ID: 15908392
[TBL] [Abstract][Full Text] [Related]
15. Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice.
Arêas AP; Oliveira ML; Miyaji EN; Leite LC; Aires KA; Dias WO; Ho PL
Biochem Biophys Res Commun; 2004 Aug; 321(1):192-6. PubMed ID: 15358234
[TBL] [Abstract][Full Text] [Related]
16. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.
Roland KL; Cloninger C; Kochi SK; Thomas LJ; Tinge SA; Rouskey C; Killeen KP
Vaccine; 2007 Dec; 25(51):8574-84. PubMed ID: 18045752
[TBL] [Abstract][Full Text] [Related]
17. A novel method for the rational construction of well-defined immunogens: the use of oximation to conjugate cholera toxin B subunit to a peptide-polyoxime complex.
Chen J; Zeng W; Offord R; Rose K
Bioconjug Chem; 2003; 14(3):614-8. PubMed ID: 12757387
[TBL] [Abstract][Full Text] [Related]
18. Pentabody-mediated antigen delivery induces antigen-specific mucosal immune response.
Li S; Zheng W; Kuolee R; Hirama T; Henry M; Makvandi-Nejad S; Fjällman T; Chen W; Zhang J
Mol Immunol; 2009 May; 46(8-9):1718-26. PubMed ID: 19269688
[TBL] [Abstract][Full Text] [Related]
19. Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate.
Matoba N; Geyer BC; Kilbourne J; Alfsen A; Bomsel M; Mor TS
Vaccine; 2006 Jun; 24(23):5047-55. PubMed ID: 16621185
[TBL] [Abstract][Full Text] [Related]
20. High-level expression of codon optimized foot-and-mouth disease virus complex epitopes and cholera toxin B subunit chimera in Hansenula polymorpha.
Song H; Zhou L; Fang W; Li Y; Wang X; Fang H; Li X; Wu M; Qiu B
Biochem Biophys Res Commun; 2004 Feb; 315(1):235-9. PubMed ID: 15013451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
